The beneficial effect of metformin on improving glycemic control and anti-inflammatory properties in type 2 diabetes patients was modulated by intestinal microbiota composition through the modulation of mucin-degrading A. muciniphila and short-chain fatty acid (SCFA)-producing microbiota [48]. Here, MUC5AC is linked to type 2 diabetes mellitus.